Disease relevance of sodium dihydroxy-oxido-oxo-phosphorane

• 2-Pentadecyl-4-hydroxymethyl-1,3-dioxolane monosodium phosphate (1) has been shown to exhibit bradycardia and hypotension in rats [1].
• The 6 diets were adequate P (7.7 g of P/kg of diet), low P (3.9 g of P/kg of diet), low P diet plus 0.75 or 1.5 g of inorganic P from monosodium phosphate, and low P diet plus the evolved Escherichia coli phytase at 500 or 1,000 units/kg of diet [2].
• Hypophosphatemia is treated best by oral administration of feed-grade monosodium phosphate [3].
• The phosphate solution prepared from sodium dihydrogen phosphate (NaH2PO4), containing 13 mg/ml phosphate and 0.5 meq/ml sodium, in the dosage 2.5-3.0 mg phosphate/Kg body weight, was administered through the central venous lins every 6-8 hours [4].

High impact information on sodium dihydroxy-oxido-oxo-phosphorane

• It involves separation by an uncoated fused-silica capillary under phosphoric acid buffer in CZE mode and by another uncoated fused-silica capillary under neutral sodium dihydrogen phosphate buffer containing sodium dodecyl sulfate in MEKC mode [5].
• 2-cis-delta 8-Heptadecenyl-4-(hydroxymethyl)-1,3-dioxolane monosodium phosphate (1b) has been shown to be present as a major component of Darmstoff in mammalian intestine and to be a potent inducer for contraction of intestinal smooth muscle [6].
• The influence of sodium dihydrogen phosphate (Pi) and glucose on the development of hamster 8-cell embryos mediated by pyruvate (P) or amino acids (A) or lactate (L) was investigated using modified Tyrode's medium, TLP-PVA [7].
• Its mobile phase consists of an acetonitrile-50 mM monosodium phosphate buffer (pH 3.0) containing 0.1% triethylamine (10:90, v/v) with a flow-rate of 0.05 ml/min [8].
• Berberine and dialysates were separated using a Zorbax SB-phenyl column and a mobile phase comprised of acetonitrile-methanol-20 mM monosodium phosphate (pH 3.0) (35:20:45, v/v) together with 0.1 mM 1-octanesulfonic acid [9].

Chemical compound and disease context of sodium dihydroxy-oxido-oxo-phosphorane

• Enterococcus faecalis PPAT has been overexpressed in Escherichia coli as a fusion with a C-terminal purification tag and crystallized at 297 K using a reservoir solution consisting of 0.1 M sodium HEPES pH 7.5, 0.8 M sodium dihydrogen phosphate and 0.8 M potassium dihydrogen phosphate [10].

Biological context of sodium dihydroxy-oxido-oxo-phosphorane

• The bioavailabilities of P (relative to MSP) for low-phytate and normal corn were 62 and 9%, respectively [11].

Anatomical context of sodium dihydroxy-oxido-oxo-phosphorane

• Sequence of expression of MyoD1 and various cell surface and cytoskeletal proteins in regenerating mouse muscle fibers following treatment with sodium dihydrogen phosphate [12].
• Whole and single fiber chorda tympani nerve recordings were obtained in 5 chimpanzees to stimulation with MSG (monosodium phosphate) and GMP (guanosine 5'-monophosphate, disodium salt) alone and in combination [13].
• Increasing levels of MSP improved gain, gain:feed, and tibia ash (linear, P < 0.01) [14].
• When mixed with a solution of 1 mol/L sodium dihydrogen phosphate, the cement set forming carbonate-containing apatite in revised, simulated body fluid (R-SBF)--which served to mimic the tissue fluid in dental pulp [15].

Associations of sodium dihydroxy-oxido-oxo-phosphorane with other chemical compounds

• The buffer solution used in this method was acetonitrile and 0.02 M sodium dihydrogen-phosphate solution adjusted to pH 7.5 with 0.05 M sodium hydroxide [16].
• A high-performance liquid chromatographic method was applied to the determination of the geniposide concentration in Gardenia fruit and preparations of traditional Chinese medicine using a mobile phase of acetonitrile-methanol-5 mM monosodium phosphate (pH 4.6) (5:15:80, v/v/v) [17].
• The drug and the internal standard (quinine) were evaluated from a 10 microns U-Bondapack C-18 cartridge at ambient temperature with a mobile phase consisting of acetonitrile: 0.1 M sodium dihydrogen phosphate (20:80%, v/v) adjusted to pH 3.9 with phosphoric acid, and at a flow rate of 2.5 ml/min [18].
• One hundred millimolars sodium tetraborate buffer containing 20mM sodium dihydrogen phosphate with a final pH 9.8 was used as a running buffer [19].
• Isocratic elution of cephaloridine was carried out with a mobile phase containing methanol-20 mM monosodium phosphate (25:75, v/v, pH 5.5), and the flow rate of the mobile phase was 0.05 mL/min within 10 min [20].

Gene context of sodium dihydroxy-oxido-oxo-phosphorane

• An eluent of 0.3 M sodium dihydrogen phosphate was pumped at a flow rate of 1 mL/min and the columns were maintained at 40 degrees C. CDDP was eluted at about 11 min and the identity of the peak of CDDP on the chromatogram was confirmed by its 3-dimensional chromatogram and analysis of platinum in the column effluent [21].
• HPLC separation was achieved on a C18 column with the mobile phase of acetonitrile-50 mM sodium dihydrogen phosphate (60:40, v/v) at a flow-rate of 1 ml/min [22].
• The acid denaturation of bovine pancreatic ribonuclease A in the presence of 0.2M sodium dihydrogen phosphate has been studied by n.m.r. spectroscopy [23].

Analytical, diagnostic and therapeutic context of sodium dihydroxy-oxido-oxo-phosphorane

• For determination of BAL and BE with head space-capillary gas chromatography, water and HCl or sodium dihydrogen phosphate were added to the sample [24].
• Extracts were analyzed by high-performance liquid chromatography using an isocratic solvent system of acetonitrile and aqueous solution (15/85 v/v) consisting of 0.015 M sodium salt of l-heptane-sulfonic acid, 0.002 M tetramethylammonium bromide, and 0.01 M sodium dihydrogen phosphate adjusted to pH 3.0 with phosphoric acid [25].
• V, M1-M3 were resolved using an HPLC gradient program with a mobile phase consisting of 60-75% methanol:acetonitrile (70:30) and 0.05 M monobasic sodium phosphate buffer pH 3.3 at 1 ml/min, a C18 column, and monitored at 212 nm [26].
• A Raman spectroscopy method for determining the drug content of street samples of amphetamine was developed by dissolving samples in an acidic solution containing an internal standard (sodium dihydrogen phosphate) [27].
• Surviving alpacas recovered after treatment with monosodium phosphate and an oral Vitamin D supplement [28].

References